Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus FOAMCOAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus FOAMCOAT.
BENSULFOID vs FOAMCOAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Bensulfoid: not a recognized drug. No data available.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic